Pages that link to "Q40154550"

The following pages link to EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways (Q40154550):

Displaying 44 items.

• The role of the EP receptors for prostaglandin E2 in skin and skin cancer (Q26999707) (← links)
• HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells (Q28270184) (← links)
• Monitoring Endothelial and Tissue Responses to Cobalt Ferrite Nanoparticles and Hybrid Hydrogels (Q28468462) (← links)
• Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis (Q28481397) (← links)
• Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. (Q30855607) (← links)
• Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma (Q31016138) (← links)
• Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection (Q33651797) (← links)
• Lead optimization studies of cinnamic amide EP2 antagonists (Q33654575) (← links)
• Prostanoid receptor EP2 as a therapeutic target (Q33711678) (← links)
• PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells (Q33761715) (← links)
• Development of second generation EP2 antagonists with high selectivity (Q33939410) (← links)
• A novel protein from the serum of Python sebae, structurally homologous with type-γ phospholipase A(2) inhibitor, displays antitumour activity. (Q33990746) (← links)
• International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress (Q34200165) (← links)
• The Prostaglandin E2 Receptor, EP2, Stimulates Keratinocyte Proliferation in Mouse Skin by G Protein-dependent and β-Arrestin1-dependent Signaling Pathways (Q34400793) (← links)
• Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma (Q35145204) (← links)
• Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells (Q35673201) (← links)
• Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis (Q35847666) (← links)
• EP2 and EP4 receptors on muscularis resident macrophages mediate LPS-induced intestinal dysmotility via iNOS upregulation through cAMP/ERK signals (Q35849983) (← links)
• mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity (Q35921941) (← links)
• Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway (Q36334079) (← links)
• Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. (Q36573214) (← links)
• Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2. (Q36833728) (← links)
• The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development (Q37329206) (← links)
• Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer (Q37536891) (← links)
• Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma (Q37668834) (← links)
• Cyclooxygenase-2 in oncogenesis (Q37824155) (← links)
• PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells (Q38047052) (← links)
• Role of platelets in inflammation and cancer: novel therapeutic strategies (Q38151957) (← links)
• The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest, and inhibits prostaglandin E2-induced proliferation in oral squamous carcinoma Tca8113 cells. (Q38710579) (← links)
• Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells (Q38759898) (← links)
• Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: involvement of protein kinase C-θ activation (Q38914626) (← links)
• EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity (Q39443547) (← links)
• Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells (Q39633037) (← links)
• PGE2 Promotes the Migration of Mesenchymal Stem Cells through the Activation of FAK and ERK1/2 Pathway. (Q40980028) (← links)
• Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation. (Q41916401) (← links)
• Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation (Q42142390) (← links)
• The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB‐exposed mouse skin (Q42754872) (← links)
• Inhibition of cell cycle progression by the hydroxytyrosol-cetuximab combination yields enhanced chemotherapeutic efficacy in colon cancer cells (Q46603127) (← links)
• PGE2 mediates EGFR internalization and nuclear translocation via caveolin endocytosis promoting its transcriptional activity and proliferation in human NSCLC cells. (Q52337438) (← links)
• The metal-nonoate Ni(SalPipNONO) inhibits in vitro tumor growth, invasiveness and angiogenesis. (Q52641583) (← links)
• Transactivation of EGFR by prostaglandin E2 receptors: a nuclear story? (Q53666709) (← links)
• Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. (Q54522319) (← links)
• Peripherally restricted, highly potent, selective, aqueous-soluble EP2 antagonist with anti-inflammatory properties (Q58608077) (← links)
• Nitric Oxide Inhibits the Proliferation and Invasion of Pancreatic Cancer Cells through Degradation of Insulin Receptor Substrate-1 Protein (Q84599721) (← links)